

# Flux Bone Cement and Flux G Bone Cement



- Reduced viscosity – flexibility to fit different needs and applications
- Clinically proven and reliable performance<sup>1-9</sup>
- Flux G Bone Cement includes gentamicin – broad antibacterial spectrum and proven high release<sup>10,11\*</sup>

# Flux Bone Cement and Flux G Bone Cement

Zimmer Biomet has decades of experience in bone cement and cementing systems. With the introduction of the Flux Bone Cement and Flux G Bone Cement, we complement and expand our bone cement family with a reduced viscosity cement. Flux Bone Cements can perform as either medium or low viscosity, thereby offering an option for every surgeon's needs.

With a reduced viscosity the cement will flow more easily which makes it ideal for syringe filling used in a lot of anatomical applications. In addition, the Flux Bone Cements could be an option for larger joints arthroplasty when a low or medium viscosity alternative is preferred.

## REDUCED VISCOSITY – A BONE CEMENT WITH EASY FLOW

- Has reduced viscosity and can either perform as a medium or low viscosity bone cement depending on the time and temperature, thereby offering the flexibility to fit different needs and preferences.

## CLINICALLY PROVEN WITH RELIABLE LONG-TERM RESULTS<sup>1-9#</sup>

- When used in total hip arthroplasty, 2, 5 and 10-year RSA data, collected on bone cement equivalent to Flux Bone Cement, show satisfactory results with performance equivalent to the control group bone cement.<sup>1-5</sup> When used in total knee arthroplasty Flux G Bone Cement demonstrated excellent survival rate at 5-year follow-up.<sup>6</sup> In addition, data from the Scandinavian registers (Norway and Sweden) demonstrated survival rate in total hip and knee arthroplasty similar to other bone cements.<sup>7-9</sup>


## MECHANICAL PROPERTIES EXCEEDING INTERNATIONAL STANDARDS<sup>11,12\*</sup>

- The mechanical properties of bone cement are tested for compressive strength, bending strength and bending modulus according to ISO 5833.<sup>12</sup> Flux Bone Cement and Flux G Bone Cement meet the applicable requirements of this standard.<sup>13\*</sup>

## HANDLING PROPERTIES


Handling properties are highly dependent on the temperatures of the bone cement and the operating room. Higher temperatures provides a shorter working phase and a faster setting time. It is therefore very important that the cement user becomes familiar with the cement properties, handling and use, and uses the same standardized handling technique every time.

## FLUX BONE CEMENT AND FLUX G BONE CEMENT NON-PRECHILLED, MANUAL APPLICATION



#Data were collected on an equivalent devices of the Legal Manufacture.

## GENTAMICIN COVERAGE<sup>21</sup>



### ANTIBIOTIC-LOADED BONE CEMENT FOR REDUCED RISK OF REVISION<sup>14-17</sup>

Flux Bone Cement includes 1g active gentamicin per 40g unit.


The majority of all bacteria that can be isolated during hip operations are gram-positive, with staphylococci having the greatest share. Among gram-negative bacteria, *E. coli* and pseudomonas are the most common.<sup>18,19</sup>

Antibiotic-loaded bone cement has been shown to reduce post-op infection (or the risk of revision) following total hip and total knee replacement when combined with peri-operative antibiotic prophylaxis.<sup>14-17</sup> It might thereby also reduce associated costs.<sup>20</sup>

### GENTAMICIN – FOR BROAD COVERAGE

Gentamicin has shown to be the antibiotic of choice for bone cement, as its broad therapeutic spectrum covers gram-positive and gram-negative bacteria. Gentamicin is bactericidal on proliferating and resisting pathogens, and its release from the bone cement is superior to that of other antibiotics.<sup>21</sup>

### GENTAMICIN RELEASE FLUX G BONE CEMENT



**Flux G Bone Cement has shown to provide high local concentrations of gentamicin over several days.<sup>10\*</sup>**

## Ordering Information

Description	Size	Units per box	Part Number
Flux Bone Cement	1 x 40g	1	110043027
Flux G Bone Cement	1 x 40g	1	110043028

### References

- Söderlund, P. *et al.* 10 year results of a new low-monomer cement. *Acta Orthopaedica*. 83(6):604-8, 2012.
- Pitto, RP *et al.* Cemex Genta bone cement in total hip arthroplasty. Clinical outcome and radiostereoanalysis of 25 hips with 2-year follow-up. South Auckland Clinical School, 2003.
- Pitto, RP Cemex System Genta bone cement in total hip arthroplasty: clinical outcome and radiostereoanalysis. A 5-year follow-up. South Auckland Clinical School, 2007.
- Dahl, J., *et al.* Less wear with aluminium-oxide heads than cobalt-chrome heads with ultra-high molecular weight cemented polyethylene cups: a ten-year follow-up with radiostereometry. *International Orthopaedics*. 36(3):485-90, 2012.
- Nivbrant, B *et al.* Bone cement with reduced proportion of monomer in total hip arthroplasty: pre-clinical evaluation and randomized study of 47 cases with 5 years' follow-up. *Acta Orthopaedica Scandinavica*. 72(6):572-84, 2001.
- Cacciola, G., *et al.* Does the medial pivot knee improve the clinical and radiographic outcome of total knee arthroplasty? A single centre study on two hundred and ninety-seven patients. *International Orthopaedics*. 44(2):291-99, 2020.
- Norwegian Arthroplasty Register (NAR). Survival rate – Hip arthroplasty. Report 2017.
- Norwegian Arthroplasty Register (NAR). Survival rate – Knee arthroplasty. Report 2017.
- Swedish Hip Arthroplasty Register (SHAR). Survival rate – Hip arthroplasty. Report 2018
- Squire, MW, *et al.* Premixed Antibiotic Bone Cement. An In Vitro Comparison of Antimicrobial Efficacy. *The Journal of Arthroplasty*. 23(6), Suppl. 1, 2008.
- Data on file at TECRES S.P.A. Clinical Data & AB Release, Exolent Genta LV.
- ISO 5833, Implants for Surgery-Acrylic Resin Cements, 2002.
- Data on file at TECRES S.P.A Flux and Flux G Bone Cement Characterization.
- Colas, S., *et al.* Association Between Total Hip Replacement Characteristics and 3-Year Prosthetic Survivorship. A Population-Based Study. *JAMA Surgery*. 150 (10), p. 979-98, 2015.
- Parvizi, J., *et al.* Efficacy of antibiotic-impregnated cement in total hip replacement. A meta-analysis. *Acta Orthopaedica Scandinavica*. 79 (3 ): 335-41, 2008.
- Leong JW, *et al.* Is the use of antibiotic-loaded bone cement associated with a lower risk of revision after primary total hip arthroplasty? *Bone & Joint Journal*. Aug;102-B(8):997-1002, 2020. doi: 10.1302/0301-620X.102B8.BJJ-2020-0120.R1. PMID: 32731820.
- Jameson SS, *et al.* Antibiotic-loaded bone cement is associated with a lower risk of revision following primary cemented total knee arthroplasty: an analysis of 731,214 cases using National Joint Registry data. *Bone & Joint Journal*. Nov;101-B(11):1331-47, 2019. doi: 10.1302/0301-620X.101B11.BJJ-2019-0196.R1. PMID: 31674244.
- Kayser, F.H. *et al.* Bacteriological aspects of deep wound sepsis after total hip arthroplasty. In Marti, R. K. (Ed.). *Progress in cemented total hip surgery and revision. Proceedings of a symposium*. Amsterdam. October 16, 1982. Excerpta Medica. 7-17, 1983.
- Steinbrink, K., *et al.* Behandlung der periprotetischen Infektion der Hüfte durch einzeitige Austauschoperation. (Treatment of periprotetic infection of the hip by a onestage exchange operation). *Orthopäde*. 24: 335-43, 1995.
- Cummins, J.S., *et al.* Cost-Effectiveness of Antibiotic-Impregnated Bone Cement Used in Primary total Hip Arthroplasty. *The Journal of Bone and Joint Surgery American*. 91: 634-41, 2009.
- Kühn, K-D. *Bone Cements, Up-to-Date Comparison of Physical and Chemical Properties of Commercial Materials*. pp. 254-58. Springer Verlag: Berlin, 2000.

\*Laboratory studies not necessarily indicative of clinical performance.

All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet. This material is intended for health care professionals, Zimmer Biomet employees, and the Zimmer Biomet sales force. Distribution to any other recipient is prohibited. For indications, contraindications, warnings, precautions, potential adverse effects and patient counselling information, see the package insert or contact your local representative; visit [www.zimmerbiomet.com](http://www.zimmerbiomet.com) for additional product information. Not for distribution in France.

©2021 Zimmer Biomet



 **Legal Manufacturer**  
TECRES S.P.A.  
Via A. Doria, 6  
37066 Sommacampagna  
(VR) Italy